IAA
BMRN icon

Ironsides Asset Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ironsides Asset Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,336
Closed -$207K – 84
2023
Q3 		$207K Sell
2,336
-400
-15% -$35.6K 0.09% 63
2023
Q2 		$237K Sell
2,736
-200
-7% -$18.8K 0.1% 69
2023
Q1 		$285K Hold
2,936
– – 0.13% 61
2022
Q4 		$304K Hold
2,936
– – 0.14% 58
2022
Q3 		$249K Buy
2,936
+30
+1% +$2.67K 0.11% 66
2022
Q2 		$241K Sell
2,906
-30
-1% -$2.39K 0.09% 71
2022
Q1 		$226K Hold
2,936
– – 0.07% 85
2021
Q4 		$259K Sell
2,936
-1,390
-32% -$115K 0.07% 77
2021
Q3 		$334K Sell
4,326
-2,000
-32% -$158K 0.11% 69
2021
Q2 		$528K Sell
6,326
-1,040
-14% -$82.4K 0.16% 46
2021
Q1 		$556K Buy
7,366
+20
+0.3% +$1.63K 0.17% 43
2020
Q4 		$644K Buy
7,346
+160
+2% +$12.7K 0.2% 45
2020
Q3 		$547K Sell
7,186
-2,969
-29% -$300K 0.17% 54
2020
Q2 		$1.25M Hold
10,155
– – 0.41% 25
2020
Q1 		$858K Buy
10,155
+6,175
+155% +$532K 0.52% 23
2019
Q4 		$337K Sell
3,980
-10,955
-73% -$827K 0.11% 76
2019
Q3 		$1.01M Hold
14,935
– – 0.34% 39
2019
Q2 		$1.28M Buy
14,935
+3,915
+36% +$335K 0.43% 31
2019
Q1 		$979K Hold
11,020
– – 0.32% 34
2018
Q4 		$938K Buy
11,020
+7,525
+215% +$716K 0.34% 33
2018
Q3 		$339K Hold
3,495
– – 0.1% 86
2018
Q2 		$329K Hold
3,495
– – 0.11% 88
2018
Q1 		$283K Sell
3,495
-200
-5% -$17.2K 0.11% 81
2017
Q4 		$329K Hold
3,695
– – 0.13% 76
2017
Q3 		$344K Buy
+3,695
New +$327K 0.14% 75

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ironsides Asset Advisors's BMRN Position: Q4 2023 in Review

Ironsides Asset Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 2,336 shares — an estimated $207K sold.

Ironsides Asset Advisors first reported a position in BMRN in Q3 2017 and held it in 25 quarters. The position peaked at $1.28M in Q2 2019. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

  • Ironsides Asset Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Ironsides Asset Advisors sold 2,336 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $207K.
  • Ironsides Asset Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 25 quarters.
  • Ironsides Asset Advisors's BioMarin Pharmaceuticals position peaked at $1.28M in Q2 2019.
  • 547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Ironsides Asset Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.